言語を選択

FGF-21

FGF-21 詳細

英語名	Fibroblast growth factor 21	市販薬剤の数	0
治験薬の数	10	ターゲットの別称	FGF21
研究＆開発段階	Phase 3 Clinical

英語名	Fibroblast growth factor 21
ターゲットの別称	FGF21
市販薬剤の数	0
治験薬の数	10
研究＆開発段階	Phase 3 Clinical

FGF-21 製品リスト

属性
Protein (2)Cell (1)Kits (1)
製品ライブラリ
オンライン (4)
種
Human (4)
タグ
His Tag (1)His Tag & Avi Tag (1)- (2)
マーカー
Unconjugated (1)Biotin-labeled (1)- (2)

製品番号	種	発現システム	製品説明
HOT FG1-H5243	Human	HEK293	Human FGF-21 Protein, His Tag (SPR verified)
CEA-B268	Human	-	Human FGF-21 ELISA Kit
CHEK-ATF163	Human	HEK293	Human FGF-21 (Luc) HEK293 Reporter Cell
FG1-H82Q3	Human	HEK293	Biotinylated Human FGF-21 Protein, His,Avitag™

総数量4

FGF-21バックグランド

Fibroblast growth factor 21 (FGF21), which stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression. FGF21 has been shown to protect animals from diet-induced obesity when overexpressed in transgenic mice. It also lowers blood glucose and triglyceride levels when administered to diabetic rodents, suggesting it may exhibit the therapeutic characteristics necessary for effective treatment of diabetes. Treatment of animals with FGF21 results in increased energy expenditure, fat utilisation and lipid excretion. FGF21 is most abundantly expressed in the liver, and also expressed in the thymus at lower levels.

FGF-21分子の別称

FGF-21, FGF21

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Pegozafermin	BIO89-100; TEV-47948	Phase 3 Clinical	Teva Pharmaceutical Industries Ltd	Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease	詳細
Efimosfermin alfa	LLF-580; BOS-580; GSK-6519754	Phase 3 Clinical	Novartis Pharma Ag	Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity	詳細
Efruxifermin	AKR-001; AMG-876; EFX; Fc-FGF21(RGE)	Phase 3 Clinical	Amgen Inc	Diabetes Mellitus; Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease	詳細
MWN-105	MWN-105	Phase 2 Clinical	Shanghai Minwei Biotechnology Co Ltd	Diabetes Mellitus, Type 2; Hyperlipidemias; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight	詳細
TQA-2225	AP-025; TQA2225; TQA-2225	Phase 2 Clinical	Anyuan Pharmaceutical Technology (Shanghai) Co Ltd	Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease	詳細
HEC-88473	HEC-88473; HEC88473; APL-18881	Phase 2 Clinical	Dongguan Hec Taigen Biopharmaceuticals Co Ltd	Diabetes Mellitus, Type 2; Hepatitis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity	詳細
B-1344	B-1344	Phase 1 Clinical	Tasly Biomedical Co Ltd	Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease	詳細
DMR-2301	DMR-2301; DMR2301	Phase 1 Clinical	Shanghai Duomirui Biotechnology Co Ltd	Metabolic Dysfunction-Associated Steatotic Liver Disease	詳細
ZT-003	ZT003; ZT-003	Phase 1 Clinical	Beijing QL Biopharmaceutical Co Ltd	Diabetes Mellitus; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity	詳細
AP-026	TQA2226; AP026; AP-026; TQA-2226	Phase 1 Clinical	Anyuan Pharmaceutical Technology (Shanghai) Co Ltd	Diabetes Mellitus, Type 2; Hyperlipidemias; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight	詳細